Pifeltro (doravirine) is a prescription medication used in combination with other antiviral medicines to treat HIV-1 infected adults. It is classified as a non-nucleoside reverse transcriptase inhibitor (NNRTI), which helps inhibit the reverse transcriptase enzyme that HIV uses to make copies of its RNA. By inhibiting this enzyme, Pifeltro helps to inhibit the replication cycle of the virus, preventing it from spreading in the body.

HIV-1 is a virus that infects and weakens the immune system. As the virus replicates and spreads, it can eventually lead to acquired immunodeficiency syndrome (AIDS). Pifeltro helps suppress viral replication, which results in a reduction of the viral load in the body, which in turn helps to slow down the progression of the disease and reduce the risk of developing AIDS.

Pifeltro is supplied as a 100- milligram tablet, which is taken orally once a day with or without food. It may be taken in combination with other medications to create an effective treatment plan. Patients should discuss their treatment options with their healthcare provider to determine the best combination of antiviral medicines to treat their unique condition.

As with any medication, Pifeltro can come with potential side effects. However, the side effects are generally mild and temporary, and include headache, nausea, diarrhea, and fatigue. Serious side effects such as allergic reactions and liver problems are rare but should be reported immediately to a healthcare provider if experienced.

It is important to note that Pifeltro is not a cure for HIV-1 and it cannot prevent the spread of the virus. It is intended to be used as part of a comprehensive treatment plan that includes frequent viral load testing and regular monitoring by a healthcare professional. Regular monitoring is important because the virus can mutate and become resistant to certain medications over time, so it is important to test the viral load regularly to ensure the medication is still effective.

Before taking Pifeltro, patients should inform their healthcare provider of any allergies or medical conditions they have, as well as medications they are currently taking. Certain medications can interact with Pifeltro, reducing its effectiveness, or increasing the risk of side effects. Patients should not stop taking Pifeltro without consulting their healthcare provider first.

In conclusion, Pifeltro is an important medication used to treat HIV-1 infected adults. It works by suppressing the replication of the virus, which can slow down the progression of the disease and reduce the risk of developing AIDS. Patients should take Pifeltro as directed by their healthcare provider, maintain regular follow-up visits, and discuss any concerns or potential risks with their provider.